CURX

8-K - Curanex Pharmaceuticals Inc (0002025942) (Filer)

10-Q - Curanex Pharmaceuticals Inc (0002025942) (Filer)

8-K - Curanex Pharmaceuticals Inc (0002025942) (Filer)

Expanded case series includes advanced thymic carcinoma, small cell lung cancer, pancreatic cancer, end-stage liver cirrhosis, and end-stage renal disease According to patient accounts, multiple critically ill patients with very poor prognoses reported meaningful improvements in functional status, appetite, mobility, and overall condition after taking the Company's product Jericho, New York, April 08, 2026 (GLOBE NEWSWIRE) -- Curanex Pharmaceuticals, Inc. (NASDAQ:CURX) ("Curanex" or the "Company"), a pharmaceutical development company focused on advancing therapeutic assets for serious diseases with significant unmet medical need, today highlighted five additional patient cases that mana

Case involving senior dosimetrist at a premier cancer hospital in the Northeast suggests potential relevance of Phyto-N in one of oncology's most serious and underserved supportive-care markets Jericho, New York, April 06, 2026 (GLOBE NEWSWIRE) -- Curanex Pharmaceuticals, Inc. (NASDAQ:CURX) ("Curanex" or the "Company"), a pharmaceutical development company focused on advancing therapeutic assets for serious diseases with significant unmet medical need, today highlighted a patient case study that management believes further supports the Company's strategic interest in treatment of cancer cachexia, a serious cancer-associated wasting syndrome marked by progressive weight loss, muscle deplet

8-K - Curanex Pharmaceuticals Inc (0002025942) (Filer)

10-K - Curanex Pharmaceuticals Inc (0002025942) (Filer)

Phyto-N 28-Day Repeat-Dose Study in Rats and Dogs Shows No Findings of Toxicological Significance at Maximum Feasible Dose, Enabling Advancement to GLP Toxicology Program Jericho, New York, March 18, 2026 (GLOBE NEWSWIRE) -- Curanex Pharmaceuticals, Inc. (NASDAQ:CURX) ("Curanex" or the "Company"), a development-stage pharmaceutical company focused on the discovery and development of botanical drugs for inflammatory diseases, today announced the successful completion of a dose-range finding toxicology study of its lead botanical drug candidate, Phyto-N, conducted in Sprague-Dawley rats and dogs. The study evaluated repeat-dose oral tolerability over 28 days and is designed to inform dose s

New Appointments Bring Deep Expertise in Immunology and Infectious Disease to Advance IND Submission and Intellectual Property Strategy Jericho, New York, March 12, 2026 (GLOBE NEWSWIRE) -- Curanex Pharmaceuticals Inc. (NASDAQ:CURX) ("Curanex" or the "Company"), a development-stage pharmaceutical company focused on the discovery and development of botanical drugs for the treatment of inflammatory diseases, today announced the appointment of two highly respected and accomplished life sciences research experts to the Company's Scientific Advisory Board. Dr. Taku Kambayashi and Dr. Selvakumar Subbian bring world-class expertise in immunology and infectious disease, directly aligned with the

New Advisors Bring 50+ Years of Leadership Experience With 2 of the Top 10 Global Pharmaceuticals Companies Jericho, New York, March 11, 2026 (GLOBE NEWSWIRE) -- Curanex Pharmaceuticals Inc. (NASDAQ:CURX) ("Curanex" or the "Company"), a development-stage pharmaceutical company focused on the discovery and development of botanical drugs for the treatment of inflammatory diseases, today announced the appointment of two highly respected and accomplished life sciences research experts to the Company's Scientific Advisory Board. Together, Dr. Daniel Pascheles and Dr. Nicholas A. Meanwell have contributed more than 75 years of total pharmaceuticals experience, including a combined 50 years at M

8-K - Curanex Pharmaceuticals Inc (0002025942) (Filer)

Board Includes Former Fortune 100 Pharma Executive and Leading US Medical Research Academic Jericho, New York, March 05, 2026 (GLOBE NEWSWIRE) -- Curanex Pharmaceuticals Inc. (NASDAQ:CURX) ("Curanex" or the "Company"), a development-stage pharmaceutical company focused on the discovery and development of botanical drugs for the treatment of inflammatory diseases, today announced the formation of a new Scientific Advisory Board, reporting to and supporting the executive team and Board of Directors of Curanex. The purpose of this Scientific Advisory Board will be two-fold. First, the Advisory Board will support all research and development, including upcoming clinical trials, technical sup

Company Completes GMP Pilot for Phyto-N, Targets Ulcerative Colitis IND Submission Q4 2026 Jericho, New York, Feb. 25, 2026 (GLOBE NEWSWIRE) -- Curanex Pharmaceuticals Inc. (NASDAQ:CURX) ("Curanex" or the "Company"), a development-stage pharmaceutical company focused on the discovery and development of botanical drugs for the treatment of inflammatory diseases, today announced the completion of a Good Manufacturing Practice (GMP)-compliant pilot-scale batch of its lead botanical drug candidate, Phyto-N. This pilot marks a key manufacturing milestone in preparation for its planned Investigational New Drug (IND) submission for ulcerative colitis. Since completing its initial public offerin

8-K - Curanex Pharmaceuticals Inc (0002025942) (Filer)

10-Q - Curanex Pharmaceuticals Inc (0002025942) (Filer)

NT 10-Q - Curanex Pharmaceuticals Inc (0002025942) (Filer)

8-K - Curanex Pharmaceuticals Inc (0002025942) (Filer)

Jericho, New York, Oct. 22, 2025 (GLOBE NEWSWIRE) -- Curanex Pharmaceuticals Inc. (NASDAQ:CURX) ("Curanex" or the "Company"), a developmental-stage pharmaceutical company focused on discovering and developing botanical drugs for inflammatory diseases, has engaged Strategic Investor Relations, LLC, a premier investor relations firm, to enhance Curanex's visibility in the financial community and support its ongoing efforts to engage and educate current and potential investors about the Company's innovative pipeline and strategic initiatives. With this new partnership, Curanex aims to refine its communication strategies and investor relations activities to ensure stakeholders are fully infor

8-K - Curanex Pharmaceuticals Inc (0002025942) (Filer)

8-K - Curanex Pharmaceuticals Inc (0002025942) (Filer)

Jericho, New York, Sept. 12, 2025 (GLOBE NEWSWIRE) -- Curanex Pharmaceuticals Inc. (NASDAQ:CURX) ("Curanex" or the "Company"), a developmental stage pharmaceutical company focused on discovering and developing botanical drugs for inflammatory diseases, today announced that Dominari Securities LLC, which acted as the lead underwriter for the Company's underwritten initial public offering (the "Offering" or the "IPO"), has exercised in full the over-allotment option the Company granted to the underwriters and purchased additional 562,500 shares of common stock of the Company at the IPO price of $4.00 per share. As a result of the sale of these 562,500 shares, the Company has raised an addit

10-Q - Curanex Pharmaceuticals Inc (0002025942) (Filer)

3 - Curanex Pharmaceuticals Inc (0002025942) (Issuer)

3 - Curanex Pharmaceuticals Inc (0002025942) (Issuer)

3 - Curanex Pharmaceuticals Inc (0002025942) (Issuer)